Catalyst Dossier · compiled by CeliA 🧫
Citius Pharmaceuticals, Inc. (CTXR)
Pharmaceutical Preparations · market cap $15M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Citius Pharmaceuticals (CTXR) is a micro-cap pharmaceutical company with a $14M market cap and 23 employees, focused on hemorrhoid treatments. Its lead asset Monad 1 is in Phase 2, alongside a hydrocortisone acetate/lidocaine hydrochloride combination also in Phase 2 for the same indication. The company carries $295.4M in net debt against $4.6M in cash, implying roughly one month of runway.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Monad 1 | Phase 2 | Hemorrhoids |
Price & technical context
3-month
+5.8%
6-month
-10.3%
12-month
-47.5%
52-wk range
$0.48–$1.82
vs 50-day MA
+18.0%
vs 200-day MA
-18.6%
Realized vol
108.2%
Max drawdown
-98.1%
Daily closes through 2026-08-10. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CTXR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.